Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy

Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy

Chemotherapy is one of reliable and proven methods of malignant tumor and blood diseases treatment but however the drug side effects (particularly cardiotoxicity) occur. More often cardiovascular complications connect with anthracyclines and related drugs (doxorubicin, daunorubicyn, epirubicyn, idar...

Full description

Bibliographic Details
Main Authors:	A.-S. O. Bady, S. S. Fedorova, D. A. Yakhontov, T. I. Pospelova
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Siberian Branch Publishing House 2020-05-01
Series:	Сибирский научный медицинский журнал
Subjects:	cardiotoxicity anthracyclines non-hodgkin’s lymphoma chemotherapy doxorubicin ntprobnp cardiomyopathy
Online Access:	https://sibmed.elpub.ru/jour/article/view/374

Similar Items

Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin’s lymphoma
by: Dino Amadori
Published: (2011-10-01)

Cardiotoxicity of doxorubicin – causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022-11-01)

Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity
by: Aisling Barrett, et al.
Published: (2023-01-01)

Anthracyclines: a cornerstone in the management of non-Hodgkin’s lymphoma
by: Stefano Luminari, et al.
Published: (2011-10-01)

Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report
by: Camille Cotteret, et al.
Published: (2020-04-01)

Association of Genetic Variants at TRPC6 With Chemotherapy-Related Heart Failure
by: Nadine Norton, et al.
Published: (2020-08-01)

Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
by: Pooja P. Advani, et al.
Published: (2023-05-01)

Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023-01-01)

Case studies of elderly patients with non-Hodgkin's lymphoma
by: Stefano Luminari, et al.
Published: (2011-10-01)

The risk of peripartum cardiomyopathy among pediatric, adolescent, and young adult cancer patients exposed to doxorubicin: an opinion article
by: Christina Carfagnini, et al.
Published: (2024-11-01)

Prevention and management of anthracycline induced cardiotoxicity: A review
by: Ian Osoro, et al.
Published: (2022-12-01)

High Sensitivity Troponin T as Complementary Modality for Determining Doxorubicin Regimen Cardiotoxicity in Non-Hodgkin Lymphoma Patients
by: Ami Ashariati Prayogo, et al.
Published: (2022-01-01)

Electrocardiographic characteristics of Nigerian children on anthracycline-based chemotherapy: A preliminary report
by: I D Peter, et al.
Published: (2017-01-01)

Subclinical Anthracycline-Induced Cardiotoxicity in the Long - Term Follow-Up of Lymphoma Survivors: A Multi-Layer Speckle Tracking Analysis
by: Yu Kang, et al.

Predictive Factors of Therapy-Related Cardiovascular Events in Patients with Lymphoma Receiving Anthracyclines
by: Alberto Lopez-Garcia, et al.
Published: (2024-04-01)

The Treatment of Non-Hodgkin's Lymphomas
by: David J. Straus
Published: (2023-08-01)

The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)

The Role of Doxorubicin in the Formation of Cardiotoxicity – Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review)
by: D. A. Andreev, et al.
Published: (2024-03-01)

Anthracycline cardiomyopathy
by: Vasiliy Nefedovich Anokhin, et al.
Published: (2011-10-01)

Clinical features of oral cavity of patients with non-Hodgkin’s lymphoma undergoing chemotherapy
by: Diptakanya Murdi Suroso, et al.
Published: (2013-07-01)

SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly
by: Matti Aapro
Published: (2011-10-01)

Long-term cardiac effects of modern treatment for Hodgkin’s lymphoma
by: Anders W Bjerring, et al.
Published: (2024-04-01)

Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application
by: Tanawat Attachaipanich, et al.
Published: (2023-02-01)

Current approaches to the treatment of non-Hodgkin's lymphoma
by: Christian Gisselbrecht
Published: (2011-10-01)

Primary Extra Nodular Non-Hodgkin Lymphoma during Pregnancy: Case Report
by: Fariba Kahnamuie Agdam, et al.
Published: (2014-12-01)

Minimising chemotherapy while optimising immune therapy for paediatric nodular lymphocyte-predominant Hodgkin's lymphoma
by: Roiya Farhan, MBBS, et al.
Published: (2020-12-01)

Paraneoplastic Arthritis in a Patient with Non-Hodgkin’s Lymphoma
by: Guntur Darmawan, et al.
Published: (2017-11-01)

Retrospective Analysis of Pemetrexed-based Chemotherapy Regimens on Mid-elderly Non-Hodgkin's Lymphoma
by: WEN Tingyu, et al.
Published: (2020-02-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)

P.42 The Effects of Chemotherapy on Arterial Stiffness in Patients with Hodgkin Lymphoma
by: Constantinos Anagnostopoulos, et al.
Published: (2020-12-01)

RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS
by: N. T. Vatutin, et al.
Published: (2017-10-01)

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
by: Mani Ramzi, et al.
Published: (2015-03-01)

A case of metachronous peripheral T‐Cell non‐Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin
by: Federico Meconi, et al.
Published: (2020-08-01)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
by: Bongani Kaimila, et al.
Published: (2017-08-01)

Systemic and cardiac susceptibility of immune compromised mice to doxorubicin
by: Amanda J. Favreau-Lessard, et al.
Published: (2019-04-01)

NON-HODGKIN'S LYMPHOMA
by: Sajjad Ahmad Baloch
Published: (2015-01-01)

Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy
by: Heba F. Taha, et al.
Published: (2022-03-01)

Cardiac events among patients with sarcoma treated with doxorubicin by method of infusion: A real‐world database study
by: Lee D. Cranmer, et al.
Published: (2023-01-01)

Doxorubicin induces an alarmin-like TLR4-dependent autocrine/paracrine action of Nucleophosmin in human cardiac mesenchymal progenitor cells
by: Sara Beji, et al.
Published: (2021-06-01)

Anthracycline-Induced Cardiotoxicity
by: Radomír Hrdina, et al.
Published: (2000-01-01)